Eyepoint Pharmaceuticals logo

Eyepoint Pharmaceuticals share price today

(EYPT)

Eyepoint Pharmaceuticals share price is $7.1 & ₹603.33 as on 21 Dec 2024, 2.30 'hrs' IST

$7.1

▲

-0.02

(-0.28%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Eyepoint Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Eyepoint Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Eyepoint Pharmaceuticals. Get details on the Indian mutual funds that are investing in Eyepoint Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Eyepoint Pharmaceuticals's financials.

Eyepoint Pharmaceuticals share price movements

  • Today's Low: $6.97
    Today's High: $7.42

    Day's Volatility :6.13%

  • 52 Weeks Low: $6.90
    52 Weeks High: $30.99

    52 Weeks Volatility :77.73%

Eyepoint Pharmaceuticals Returns

PeriodEyepoint Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-14.35%
-11.1%
0.0%
6 Months
-16.67%
-6.0%
0.0%
1 Year
-69.94%
2.7%
0.0%
3 Years
-47.6%
0.6%
-19.7%

Eyepoint Pharmaceuticals Key Statistics

in dollars & INR

Previous Close
$7.12
Open
$6.96
Today's High
$7.42
Today's Low
$6.965
Market Capitalization
$485.9M
Today's Volume
$3.6M
52 Week High
$30.99
52 Week Low
$6.9
Revenue TTM
$45.7M
EBITDA
$-114.6M
Earnings Per Share (EPS)
$-1.99
Profit Margin
-226.57%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-74.68%

How to invest in Eyepoint Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Eyepoint Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Eyepoint Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Eyepoint Pharmaceuticals or EYPT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Eyepoint Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Eyepoint Pharmaceuticals shares which would translate to 0.120 fractional shares of Eyepoint Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Eyepoint Pharmaceuticals, in just a few clicks!

Returns in Eyepoint Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Eyepoint Pharmaceuticals investment value today

Current value as on today

₹1,72,137

Returns

₹72,137

(+72.14%)

Returns from Eyepoint Pharmaceuticals Stock

₹69,941 (false-69.94%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Eyepoint Pharmaceuticals

-59%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Eyepoint Pharmaceuticals on INDmoney from India has reduced in the last 30 days as on Dec 22, 2024. -59% less investors are searching Eyepoint Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Eyepoint Pharmaceuticals

  • Cormorant Asset Management, LLC

    12.20%

  • Suvretta Capital Management, LLC

    7.58%

  • Franklin Resources Inc

    5.88%

  • Adage Capital Partners Gp LLC

    5.56%

  • BlackRock Inc

    5.52%

  • Vanguard Group Inc

    4.47%

Analyst Recommendation on Eyepoint Pharmaceuticals

Buy

    93%Buy

    6%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Eyepoint Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Eyepoint Pharmaceuticals

What analysts predicted

Upside of 371.19%

Current:

$7.10

Target:

$33.45

Insights on Eyepoint Pharmaceuticals

  • Price Movement

    In the last 1 year, EYPT stock has moved down by -65.8%

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 9.47M → 10.52M (in $), with an average increase of 10.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -30.82M → -29.36M (in $), with an average increase of 5.0% per quarter

  • EYPT vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 101.3%

  • EYPT vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 71.0%

  • Price to Sales

    ForEYPT every $1 of sales, investors are willing to pay $7.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Eyepoint Pharmaceuticals Financials in INR & Dollars

FY18Y/Y Change
Revenue
$3.0M
↓ 60.72%
Net Income
$-53.2M
↑ 187.64%
Net Profit Margin
-1.8K%
↓ 1550.52%
FY19Y/Y Change
Revenue
$20.4M
↑ 587.77%
Net Income
$-63.0M
↑ 18.43%
Net Profit Margin
-309.2%
↑ 1486.51%
FY20Y/Y Change
Revenue
$34.4M
↑ 69.1%
Net Income
$-52.7M
↓ 16.39%
Net Profit Margin
-152.89%
↑ 156.31%
FY21Y/Y Change
Revenue
$36.9M
↑ 7.27%
Net Income
$-63.9M
↑ 21.39%
Net Profit Margin
-173.03%
↓ 20.14%
FY22Y/Y Change
Revenue
$41.4M
↑ 12.09%
Net Income
$-124.5M
↑ 94.81%
Net Profit Margin
-300.72%
↓ 127.69%
FY23Y/Y Change
Revenue
$46.0M
↑ 11.14%
Net Income
$-70.8M
↓ 43.14%
Net Profit Margin
-153.84%
↑ 146.88%
Q2 FY23Q/Q Change
Revenue
$9.1M
↑ 18.51%
Net Income
$-22.9M
↑ 6.18%
Net Profit Margin
-251.73%
↑ 29.23%
Q3 FY23Q/Q Change
Revenue
$15.2M
↑ 66.96%
Net Income
$-12.6M
↓ 44.97%
Net Profit Margin
-82.96%
↑ 168.77%
Q4 FY23Q/Q Change
Revenue
$14.0M
↓ 7.72%
Net Income
$-14.1M
↑ 11.79%
Net Profit Margin
-100.51%
↓ 17.55%
Q1 FY24Q/Q Change
Revenue
$11.7M
↓ 16.71%
Net Income
$-29.3M
↑ 107.7%
Net Profit Margin
-250.63%
↓ 150.12%
Q2 FY24Q/Q Change
Revenue
$9.5M
↓ 18.89%
Net Income
$-30.8M
↑ 5.27%
Net Profit Margin
-325.27%
↓ 74.64%
Q3 FY24Q/Q Change
Revenue
$10.5M
↑ 11.05%
Net Income
$-29.4M
↓ 4.75%
Net Profit Margin
-278.99%
↑ 46.28%
FY18Y/Y Change
Profit
$-15.5M
↓ 306.14%
FY19Y/Y Change
Profit
$17.7M
↓ 213.75%
FY20Y/Y Change
Profit
$28.6M
↑ 61.86%
FY21Y/Y Change
Profit
$28.8M
↑ 0.52%
FY22Y/Y Change
Profit
$33.1M
↑ 15.01%
FY23Y/Y Change
Profit
$41.4M
↑ 25.12%
Q2 FY23Q/Q Change
Profit
$7.3M
↑ 3.83%
Q3 FY23Q/Q Change
Profit
$14.0M
↑ 91.44%
Q4 FY23Q/Q Change
Profit
$13.0M
↓ 6.93%
Q1 FY24Q/Q Change
Profit
$10.9M
↓ 16.16%
Q2 FY24Q/Q Change
Profit
$8.1M
↓ 26.08%
Q3 FY24Q/Q Change
Profit
$9.8M
↑ 21.2%
FY18Y/Y Change
Operating Cash Flow
$-21.9M
↑ 6.92%
Investing Cash Flow
$-17.0M
↑ 0.4%
Financing Cash Flow
$60.7M
↑ 613.52%
FY19Y/Y Change
Operating Cash Flow
$-56.7M
↑ 158.82%
Investing Cash Flow
$-213.0K
↓ 98.74%
Financing Cash Flow
$33.9M
↓ 44.18%
FY20Y/Y Change
Operating Cash Flow
$-14.4M
↓ 74.54%
Investing Cash Flow
$-362.0K
↑ 69.95%
Financing Cash Flow
$37.5M
↑ 10.71%
FY21Y/Y Change
Operating Cash Flow
$-50.1M
↑ 247.05%
Investing Cash Flow
$-33.1M
↑ 9049.45%
Financing Cash Flow
$216.9M
↑ 478.53%
FY22Y/Y Change
Operating Cash Flow
$-65.0M
↑ 29.76%
Investing Cash Flow
$-17.3M
↓ 47.87%
Financing Cash Flow
$-690.0K
↓ 100.32%
Q2 FY23Q/Q Change
Operating Cash Flow
$57.0M
↓ 438.72%
Investing Cash Flow
$13.5M
↓ 58.03%
Financing Cash Flow
$-36.7M
↑ 616.12%

Eyepoint Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Eyepoint Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Eyepoint Pharmaceuticals Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals Inc
-20.67%
-16.67%
-69.94%
-47.6%
-53.29%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.73%
-34.03%
-17.38%
12.23%
86.41%
Biontech Se
Biontech Se
4.48%
30.56%
7.97%
-55.71%
237.85%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-0.55%
10.11%
28.37%
26.29%
108.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-11.79%
-16.36%
-2.55%
77.79%
80.12%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals Inc
NA
NA
NA
-2.22
-0.75
-0.31
NA
4.09
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
17.51
17.51
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.17
0.55
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals Inc
Buy
$485.9M
-53.29%
NA
-226.57%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$77.8B
86.41%
17.51
33.61%
Biontech Se
Biontech Se
Buy
$26.7B
237.85%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.8B
108.55%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.1B
80.12%
32.84
-4.51%

About Eyepoint Pharmaceuticals

psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
Organization
Eyepoint Pharmaceuticals
Employees
121
CEO
Dr. Jay S. Duker M.D.
Industry
Health Technology

Management People of Eyepoint Pharmaceuticals

NameTitle
Dr. Jay S. Duker M.D.
President, CEO & Director
Mr. George O. Elston CPA
Executive VP & CFO
Mr. Michael J. Maciocio
Senior Vice President of Manufacturing & Operations
Mr. Ron I. Honig Esq.
Chief Legal Officer & Company Secretary
Ms. Jennifer Leonard
Chief People Officer & Senior VP of IT
Mr. David Scott Jones M.A.
Senior VP & Chief Commercial Officer
Mr. Michael Pine
Chief Business Officer
Ms. Isabelle Lefebvre
Chief Regulatory Officer
Dr. Marcia Sellos-Moura Ph.D.
Senior VP and Head of Development & Program Management
Dr. Ramiro Ribeiro M.D., Ph.D.
Chief Medical Officer

Important FAQs about investing in Eyepoint Pharmaceuticals from India :

What is Eyepoint Pharmaceuticals share price today?

Eyepoint Pharmaceuticals share price today stands at $7.10, Open: $6.96 ; Previous Close: $7.12 ; High: $7.42 ; Low: $6.97 ; 52 Week High: $30.99 ; 52 Week Low: $6.90. The stock opens at $6.96, after a previous close of $7.12. The stock reached a daily high of $7.42 and a low of $6.97, with a 52-week high of $30.99 and a 52-week low of $6.90.

Can Indians buy Eyepoint Pharmaceuticals shares?

Yes, Indians can invest in the Eyepoint Pharmaceuticals (EYPT) from India.

With INDmoney, you can buy Eyepoint Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Eyepoint Pharmaceuticals at zero transaction cost.

How can I buy Eyepoint Pharmaceuticals shares from India?

It is very easy to buy Eyepoint Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Eyepoint Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Eyepoint Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Eyepoint Pharmaceuticals stocks?

To start investing in Eyepoint Pharmaceuticals, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Eyepoint Pharmaceuticals

Today’s highest price of Eyepoint Pharmaceuticals (EYPT) is $7.42.

Today’s lowest price of Eyepoint Pharmaceuticals (EYPT) is $6.97.

What is today's market capitalisation of Eyepoint Pharmaceuticals

Today's market capitalisation of Eyepoint Pharmaceuticals EYPT is 485.9M

What is the 52 Week High and Low Range of Eyepoint Pharmaceuticals

  • 52 Week High

    $30.99

  • 52 Week Low

    $6.90

What are the historical returns of Eyepoint Pharmaceuticals?

  • 1 Month Returns

    -20.67%

  • 3 Months Returns

    -16.67%

  • 1 Year Returns

    -69.94%

  • 5 Years Returns

    -53.29%

Who is the Chief Executive Officer (CEO) of Eyepoint Pharmaceuticals

Dr. Jay S. Duker M.D. is the current Chief Executive Officer (CEO) of Eyepoint Pharmaceuticals.